Related Experiment Video

Updated: Jun 24, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile

Rosane De Oliveira Duarte Achcar1, Marina N Nikiforova, Samuel A Yousem

  • 1Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213-2582, USA.

American Journal of Clinical Pathology
|April 17, 2009
PubMed

Insights

Micropapillary lung adenocarcinoma (MPA) frequently shows aggressive behavior. This study found K-ras, EGFR, and BRAF mutations in 73% of MPAs, suggesting a distinct molecular profile for this lung cancer subtype.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Micropapillary lung adenocarcinoma (MPA) is an aggressive subtype of lung adenocarcinoma.
  • MPA often presents at advanced stages with a poor prognosis.
  • Understanding the molecular drivers of MPA is crucial for targeted therapies.

Purpose of the Study:

  • To investigate the clinical and molecular characteristics of primary MPAs.
  • To identify the frequency and spectrum of K-ras, EGFR, and BRAF mutations in MPA.
  • To explore the correlation between cytomorphology and genetic mutations in MPA.

Main Methods:

  • Analysis of 15 primary MPA cases.
  • Genotyping for K-ras, EGFR, and BRAF mutations.
  • Fluorescence in situ hybridization (FISH) for EGFR amplification.

Main Results:

  • 11 out of 15 (73%) MPAs harbored mutually exclusive mutations.
  • K-ras mutations were found in 5 cases (33%).
  • EGFR mutations were found in 3 cases (20%).
  • BRAF mutations were found in 3 cases (20%).
  • Mutations were associated with smoking history, mucinous differentiation, and specific tumor growth patterns.
  • Cytomorphologic correlation with genetic mutations appeared less predictable in Western cohorts compared to Japanese cohorts.

Conclusions:

  • K-ras, EGFR, and BRAF mutations are disproportionately prevalent in lung adenocarcinomas with a dominant micropapillary pattern.
  • These mutations may contribute to the aggressive phenotype of MPA.
  • Further research is needed to elucidate the clinical implications of these findings in Western populations.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...